P01.141 Different timing to use bevacizumab in patients with recurrent glioblastoma: early versus delayed administration

摘要

BackgroundGlioblastoma (GBM) is the most baleful malignant brain tumor in adults. After a diagnosis of relapsed GBM, multimodality salvage treatment are not incisive enough to improve overall survival (OS) beyond a few months, and their best use and the timing is not well established. Bevacizumab (BEV) seems to improve OS. The best timing for BEV administration requires further investigation. We report the results of a monocentric experience comparing the early use of BEV with delayed administration.